Skeletal muscle injury and repair involve multiple stages such as degeneration, inflammation, regeneration, and fibrosis, with recent studies exploring ways to enhance these processes.
Antiinflammatory drugs targeting cyclooxygenase-2 can negatively impact muscle repair, while growth factors like insulin-like growth factor-1 show potential but require better delivery methods due to their short lifespan.
Neonatal skeletal muscle derived stem cells (MDSCs) demonstrate superior tissue repair compared to traditional myoblasts due to their resistance to stress, and treatments like the angiotensin II receptor blocker losartan could further improve recovery times in muscle injuries.